Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)

Jiangxi Qingfeng Pharmaceutical Co. Ltd.0 sites80 target enrollmentMarch 14, 2020

ConditionsCOVID-19

InterventionsLopinavir / ritonavir tablets combined with Xiyanping injection Lopinavir/ritonavir treatment

DrugsLopinavir / ritonavir tablets combined with Xiyanping injection Lopinavir/ritonavir treatment

Overview

Phase: Not Applicable
Intervention: Lopinavir / ritonavir tablets combined with Xiyanping injection
Conditions: COVID-19
Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Enrollment: 80
Primary Endpoint: Clinical recovery time
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay.

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Xiyanping injection has anti-inflammatory and immune regulation effects. This study is a Randomized, Parallel Controlled Clinical Study to treat patients with COVID-19 infection.

Detailed Description

The new coronavirus (COVID-19) \[1\] belongs to the new beta coronavirus. Current research shows that it has 85% homology with bat SARS-like coronavirus (bat-SL-CoVZC45), but its genetic characteristics are similar to SARSr-CoV. There is a clear difference from MERSr-COV. Since December 2019, Wuhan City, Hubei Province has successively found multiple cases of patients with pneumonia infected by a new type of coronavirus. With the spread of the epidemic, as of 12:00 on February 12, 2020, a total of 44726 confirmed cases nationwide (Hubei Province) 33,366 cases, accounting for 74.6%), with 1,114 deaths (1068 cases in Hubei Province), and a mortality rate of 2.49% (3.20% in Hubei Province). In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Xiyanping injection has anti-inflammatory and immune regulation effects. In the early clinical practice of treating severe H1N1, it was clinically concerned, and combined with conventional treatment, and achieved good results.

Registry

clinicaltrials.gov

Start Date

March 14, 2020

End Date

April 14, 2021

Last Updated

6 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Aged \>=18 years;
•Novel coronavirus pneumonia patients diagnosed by pathogenic testing;
•The patient himself participated in the study voluntarily, agreed and signed the informed consent.

Exclusion Criteria

•Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;
•Severe primary diseases that affect survival, including: uncontrolled malignant tumors, hematological diseases, and HIV that have not been metastasized in multiple places;
•Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and allergic alveolitis caused by lung tumors;
•Women who are breastfeeding or pregnant;
•Those who are known to be allergic to the ingredients contained in the research medication, or patients with allergies;
•Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months;
•Patients who have participated in other drug clinical trials within 3 months before the screening test;
•The investigator judges that he or she cannot complete or should not participate in the study (expected death within 48 hours, and the patient refuses active treatment)